Sanofi SA

Sanofi’s LTE data show duvakitug achieves 78 % remission in UC and 73 % in CD with acceptable safety, while new SCBU leadership aims to boost specialty growth and R&D investment.

Sanofi’s Phase 2b duvakitug data boost IBD prospects, a Hyderabad GCC expansion cuts costs, and new RSV vaccine Beyfortus targets a $2.8 billion market. Click to see how these moves could generate $1.1 billion annual revenue.

Sanofi’s CEO change to Belén Garijo signals a fresh strategy to navigate patent cliffs, boost its vaccine and oncology pipeline, and seize M&A opportunities for sustained growth.

Sanofi’s new CEO, strategic vaccine acquisition, and rare‑disease investment create a growth roadmap that offsets patent cliffs and boosts margins.

Sanofi’s CEO swap to Belen Garijo signals a growth‑focused pivot, paired with new vaccine and sickle‑cell deals to diversify revenue and boost R&D.

Sanofi’s Dynavax acquisition adds HEPLISAV‑B and shingles vaccine Z‑1018 to its portfolio, while rilzabrutinib earns U.S. breakthrough and Japanese orphan status, boosting future growth prospects.

Sanofi’s Dynavax acquisition boosts its vaccine line with hepatitis B and shingles, while FDA breakthrough status for rilzabrutinib expands its rare‑disease portfolio—positioning the company for 2025 growth and investor confidence.

Sanofi’s Phase III data for amlitelimab and OX40L could unlock $900 m+ in revenue, driving a shift toward value‑based contracts and boosting its competitive edge in dermatology and rheumatology.

Sanofi’s amlitelimab shows 58‑54% EASI‑75 success in new phase‑3 AD trials, with strong safety and regulatory plans targeting 2026 approvals.

Sanofi’s Phase‑3 win for amlitelimab shows early, sustained efficacy in atopic dermatitis, offering a competitive entry into the growing AD biologics market and a strategic chance to capture market share before major patent expirations.